Risperdal Lawsuit Plaintiffs Gain Support From U.S. Supreme Court

April 06, 2016 – – LegalHerald.com reports on the U.S. Supreme Court’s decision to deny Johnson & Johnson’s appeal of the $124 million judgement against the company in a Risperdal lawsuit.

Risperdal is an atypical antipsychotic drug which was approved by the FDA for the treatment of schizophrenia in adults, and in the early 2000s for the short-term treatment of acute mania and mixed episodes associated with Bipolar 1 Disorder.

The initial lawsuit was filed by the state of South Carolina in 2007 and alleged that Ortho-McNeil-Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, illegally marketed their antipsychotic drug, Risperdal. The suit claims that Janssen sent letters to doctors claiming that Risperdal was safer than other drugs and hid the risks of the drug on labels that were attached to sample packs.

Within the decision by the Supreme Court, Justice Kittredge wrote: “By 1997, Janssen also had information that Risperdal posed a serious risk of stroke, cardiac arrest, and sudden death in the elderly.” The decision continued “Despite this clinical information, it was several years before Janssen updated the Risperdal label to accurately reflect the frequency and severity of the risk of hyperprolactinemia, weight gain and diabetes, or stroke, cardiac arrest, and sudden death in the elderly.”

The initial fine that Janssen was required to pay was set at $327 million, but due to a statute of limitations regarding the warning label, the award was reduced to $136 million. The award was later reduced again by another $12 million, yet Janssen continued to appeal the decision. They stand by Risperdal, claiming that it is a safe and effective drug.

The attorneys of Banville Law understand the concerns patients who have taken or are currently taking Risperdal may have. They are working to ensure that any individual who has taken the drug and experienced health complications which they attribute to their use of Risperdal will have the opportunity to explore their legal options. Those individuals may be entitled to substantial compensation. The firm is currently offering complimentary consultations to qualified parties.

For more information on Risperdal lawsuits or to ask questions, please contact Banville Law by calling 888-997-3792.

###

Contact Banville Law:

Laurence Banville, Esq.
888-997-3792
info@banvillelaw.com
165 West End Avenue, #1H
New York, NY 10023
United States (US)

ReleaseID: 60009141